Study Investigating Enbrel Treatment for Ankylosing Spondylitis

N/ACompletedNCT00195416

Wyeth is now a wholly owned subsidiary of Pfizer526 enrolled

Overview

To identify the following problems and questions with respect to the safety and effectiveness of Enbrel during the post-marketing period as required by Korea Food and Drug Administration (KFDA)'s regulations. 1. Unknown adverse reactions, especially serious adverse reactions 2. Change of the incidences of adverse reactions under the routine drug uses 3. Factors that may affect the safety of the drug 4. Factors that may affect the effectiveness of the drug

Study Type

OBSERVATIONAL

Enrollment

526

Conditions

Ankylosing Spondylitis

Interventions

EtanerceptDRUG

Etanercept 25mg Injection, 2 times/week

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults: Severe ankylosing spondylitis (AS) in patients who do not respond adequately to previous therapy Exclusion Criteria: * Patients with known hypersensitivity to Enbrel or any component of the product * Patients with sepsis or risk of sepsis * Patients with active infections including chronic or localized infections such as tuberculosis.

Locations (3)

Unnamed facility

Gyunggi-do, South Korea

Unnamed facility

Seoul, South Korea

Unnamed facility

Seoul, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.